Free Trial
NASDAQ:CNTB

Connect Biopharma Q1 2025 Earnings Report

Connect Biopharma logo
$1.00 +0.03 (+3.25%)
As of 12:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Connect Biopharma EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Connect Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Connect Biopharma Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
9:00AM ET

Upcoming Earnings

Connect Biopharma's H1 2025 earnings is scheduled for Friday, September 5, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Connect Biopharma Earnings Headlines

What is HC Wainwright's Estimate for CNTB Q2 Earnings?
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Connect Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Connect Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Connect Biopharma and other key companies, straight to your email.

About Connect Biopharma

Connect Biopharma (NASDAQ:CNTB) Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

View Connect Biopharma Profile

More Earnings Resources from MarketBeat